Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics

Clin Infect Dis. 2020 Dec 31;71(11):2962-2964. doi: 10.1093/cid/ciaa558.

Abstract

Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.

Keywords: COVID-19; dosage regimens; drug monitoring; hydroxychloroquine; population pharmacokinetic modeling.

MeSH terms

  • Antiviral Agents* / therapeutic use
  • COVID-19* / drug therapy
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Kinetics
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Hydroxychloroquine

Supplementary concepts

  • COVID-19 drug treatment